Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 13/20 | 0.43 |
| ▸ | CTSS | P25774 | 9/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18762484 | 0.84 | CTSK (0.48) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL26129040 | 0.84 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL26129038 | 0.84 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL18762487 | 0.84 | CTSK (0.48) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3212391 | 0.84 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5450014 | 0.84 | CTSK (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2405498 | 0.84 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL10829328 | 0.82 | CTSK (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2402020 | 0.82 | CA1 (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL6826879 | 0.81 | CA1 (0.44) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CA1 4780/4885CA2 3865/4885CA7 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.